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The eﬃcacy of standard rehabilitative therapy for improving upper limb functions after stroke is limited; thus, alternative strategies
are needed. Vagus nerve stimulation (VNS) paired with rehabilitation is a promising approach, but the invasiveness of this
technique limits its clinical application. Recently, a noninvasive method to stimulate vagus nerve has been developed. The aim
of the present study was to explore whether noninvasive VNS combined with robotic rehabilitation can enhance upper limb
functionality in chronic stroke. Safety and eﬃcacy of this combination have been assessed within a proof-of-principle, double-
blind, semirandomized, sham-controlled trial. Fourteen patients with either ischemic or haemorrhagic chronic stroke were
randomized to robot-assisted therapy associated with real or sham VNS, delivered for 10 working days. Eﬃcacy was evaluated
by change in upper extremity Fugl–Meyer score. After intervention, there were no adverse events and Fugl–Meyer scores were
signiﬁcantly better in the real group compared to the sham group. Our pilot study conﬁrms that VNS is feasible in stroke
patients and can produce a slight clinical improvement in association to robotic rehabilitation. Compared to traditional
stimulation, noninvasive VNS seems to be safer and more tolerable. Further studies are needed to conﬁrm the eﬃcacy of this
innovative approach.
1. Introduction
Upper limb impairment is a common consequence of stroke
with a deep impact on patient’s quality of life. Since the eﬃ-
cacy of standard rehabilitative therapy is limited, alternative
strategies are needed. Robot-assisted rehabilitation can be
useful in stroke patients because it allows an intensive as well
as task-speciﬁc training characterized by high repetition of
movements in a strongly motivating environment [1–3].
Several studies have explored the possibility to potentiate
the eﬀect of robotic therapy by the association with nonin-
vasive human brain stimulation techniques, such as repet-
itive transcranial magnetic stimulation (rTMS), that can
induce neuroplasticity via long-term potentiation-/depres-
sion- (LTP-/LTD-) like phenomena [4]. Although intriguing,
the evidence in support of this strategy remains low [5, 6].
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Indeed, the literature analysis of the published data seems to
demonstrate that the association of rTMS with robotic train-
ing has the same clinical gain derived from robotic therapy
alone. Moreover, rTMS is contraindicated in patients who
suﬀered from haemorrhagic stroke for the risk of inducing
seizures [7]. For these reasons, there is great interest in the
development of alternative techniques of neuromodulation
that can foster the eﬀect of robotic therapy.
Vagus nerve stimulation (VNS) is approved as adjunctive
treatment for refractory epilepsy and depression but is cur-
rently under investigation for a wide range of neurological
diseases [8]. In particular, recent studies have demonstrated
that VNS paired with rehabilitation signiﬁcantly improves
forelimb strength and movement speed in rat models of
ischemic [9] and haemorrhagic stroke [10]. VNS is believed
to enhance the beneﬁts of rehabilitation by promoting neuro-
plasticity [11]. Preliminary data [12] have showed that such
approach is also feasible in patients; however, the diﬀusion
of this technique is limited by its invasiveness. Indeed, VNS
requires the surgical implantation of a stimulator of the cervi-
cal branch of the vagus nerve. Recently, it has been proposed a
noninvasive technique that consists of transcutaneous stimu-
lation of the vagus nerve (tVNS) in external auditory channel
at the inner side of the tragus. Both neuroimaging [13] and
neurophysiological [14] studies have demonstrated that the
eﬀect of tVNS on brain activity is quite similar to the eﬀect
induced by traditional, invasive VNS.
The aim of the present study was to explore whether
tVNS can enhance the beneﬁt induced by robotic rehabilita-
tion on motor function of the upper limb in chronic stroke.
Safety and eﬃcacy of this combination have been assessed
within a proof-of-principle, double-blind, semirandomized,
sham-controlled trial.
2. Material and Methods
The study was performed accordingly to the Declaration of
Helsinki and was approved by the Local Ethics Committee.
The study was proposed to patients attending the outpatient
clinic for cerebrovascular disorders of Campus Bio-Medico
University Hospital. Inclusion criteria were as follows: (a)
ﬁrst-ever, ischemic or haemorrhagic stroke at least 1 year ear-
lier; (b) hand function impairment; (c) and ability to give
informed consent and comprehend instructions. Exclusion
criteria were as follows: (a) previous surgical intervention
on vagus nerve; (b) low hearth rate (<60 bpm); (c) cognitive
impairment or any substantial decrease in alertness, language
reception, or attention that might interfere with understand-
ing instructions for motor testing; (d) apraxia; (e) excessive
pain in any joint of the paretic extremity; (f) advanced liver,
kidney, cardiac, or pulmonary disease; (g) history of signiﬁ-
cant alcohol or drug abuse; (h) depression or use of neuropsy-
chotropic drugs such as antidepressants or benzodiazepines;
(i) and pregnancy.
Fourteen patients with either ischemic or haemorrhagic
chronic stroke were randomized to robot-assisted therapy
associated with real or sham tVNS, delivered for 10 working
days. Eﬃcacy was evaluated by change in upper extremity
Fugl–Meyer assessment (FMA) score. To assess safety,
during the stimulation, heart rate (HR) and blood pressure
(BP) were monitored. Moreover, to test the tolerability of
tVNS, subjects were questioned about the presence of
unpleasant sensations or other discomforts. Each day,
patients received a session of robotic therapy immediately
following the real or sham stimulation. All patients were eval-
uated at baseline (baseline) and just after the two weeks of
treatment (post). At baseline, to evaluate neurological
impairment and disability, we also included the following
scales: National Institute of Health Stroke Scale (NIHSS),
Rankin Scale, Barthel Index, and Modiﬁed Ashworth Scale.
Spasticity was assessed by Modiﬁed Ashworth Scale at four
diﬀerent joints of aﬀected arm: the shoulder, elbow, wrist,
and ﬁngers. For each patient, a cumulative score was
obtained by summing the scores obtained in the four joints.
The cumulative score ranges from 0 (no spasticity) to 16
(maximum spasticity, i.e., score 4 in all the considered joints).
The stimulation of the auricular branch of the vagus
nerve was performed through an electric stimulator (Twis-
ter—EBM) and two Ag-AgCl electrodes (5mm in diameter)
placed in the left external acoustic meatus at the inner side
of the tragus. For sham stimulation, electrodes were attached
to the left ear lobe, an anatomical area that is outside the inner-
vation of the auricular branch of the vagus nerve. tVNS was
delivered as trains lasting 30 s and composed by 600 pulses
(intratrain pulse frequency=20Hz; pulse duration=0.3ms)
repeated every 5min for 60min. The intensity of stimulation
was individually adjusted to a level ranging above the detec-
tion threshold and below the pain threshold. To reduce the
risk of cardiac side eﬀects, only the left ear was stimulated
because vagal ﬁbers to the heart are supposed to originate
from the right side [15].
Robotic therapy was delivered at proximal or at distal
segment of the aﬀected limb according to the degree of
impairment and the choice of the physician. The InMotion2
shoulder-elbow system (Interactive Motion Technologies
Inc.) [16] was used for proximal limb segments and the
InMotion3 wrist system (Interactive Motion Technologies
Inc.) [17] for the treatment of distal segments. InMotion2
robot consists of a direct-drive mechanism that provides
two translational degrees of freedom for elbow and forearm
motion. Robot movement is enabled thanks to an impedance
control that guides or perturbs the patient’s movement. The
InMotion3 robot enables unilateral wrist training character-
ized by low endpoint inertia and friction. Flexion-extension
and radial-ulnar deviation are guaranteed thanks to two
side-mounted actuators connected to a diﬀerential mecha-
nism, while pronation-supination is actuated by another
DC motor. An impedance control is implemented to assist
patient’s movement. Each day of robotic treatment consisted
of three sessions of 320 assisted point-to-point movements,
from the center to eight outbound targets, interspersed by
four sessions of 16 unassisted recorded point-to-point move-
ments. Robot assistance at each session was tuned on
patients’ performance during the 16 point-to-point sessions.
During training, patients were required to move with a self-
paced speed in a maximum time slot of 3 s. Robotic treatment
was delivered daily for 10 consecutive working days, immedi-
ately after the end of real or sham tVNS. A physical and
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rehabilitation medicine doctor attended and assisted patients
during treatment. During the intervention period, patients
did not receive any additional physical therapy. Pharmaco-
logical therapy was also unchanged. Researchers randomiz-
ing patients and researchers delivering tVNS were not
involved in outcome assessments and data analysis; more-
over, rehabilitation doctors, patients, and researchers
involved in data analysis were blind to the type of tVNS deliv-
ered (i.e., sham or real), in order to obtain a double-blind
study design.
2.1. Statistics. Statistical analysis was performed using the
IBM SPSS Statistics (Ver. 24). After checking that the base-
line clinical measures were not diﬀerent between groups,
postintervention FMA of the two groups was expressed as
percentage of baseline scores and compared by means of
Mann–Whitney test.
In order to assess the safety of the stimulation, we mea-
sured systolic blood pressure, diastolic blood pressure, and
heart rate, before and after each stimulation, every day, for
ten days. For each of these measures, we performed a
mixed-model repeated ANOVA with days (ten levels) and
prepost (2 levels) as within subject factors and group (two
levels: real and sham) as between subject factor. Correction
for sphericity violations and multiple comparisons were
applied as needed.
3. Results
Seven patients were randomized to robot-assisted therapy
associated with real tVNS and seven patients to robot-
assisted therapy associated with sham tVNS. One sham
patient withdrew consent before the ﬁrst session of treatment.
Another sham patient withdrew because of diﬃculty in reach-
ing the hospital after the second day of treatment. Data of
these patients were not included in the analysis. Thus, a total
of 12 patients completed the study: 7 real (mean age: 53.7
± 15.6 years, 4males) and 5 sham (mean age: 55.6± 15.9 years,
3 males). The real and sham groups were not signiﬁcantly dif-
ferent regarding age, sex, type of stroke (haemorrhagic versus
ischemic), and side of lesion. Time elapsed from stroke onset
and clinical status at baseline (in particular, FMA score) were
diﬀerent between the two groups, but this diﬀerence was not
statistically signiﬁcant (p > 0 200 consistently) (Table 1).
The treatment was safe and tolerable. There were no
adverse events, unpleasant sensations, or other discomforts.
None of the patients required to stop stimulation. For systolic
BP, the ANOVA mixed model showed no signiﬁcant main
eﬀects nor signiﬁcant interactions with the factor days (p >
0 200 consistently). We however found a signiﬁcant prepost
by group interaction (F(1.9) = 7.335, p = 0 024) which was
largely related to the intergroup systolic pressure diﬀerence
(F(1.9) = 9.986, p = 0 012), as no prepost signiﬁcant diﬀer-
ences were found within each group. This analysis unveiled
that the two groups had an average signiﬁcant systolic blood
pressure diﬀerences but the stimulation has no signiﬁcant
eﬀect on this parameter (Figure 1). Similar behaviour showed
the diastolic blood pressure, for which we only found a signif-
icant prepost ∗group interaction (F(1.9) = 7.328, p = 0 024).
No signiﬁcant group diﬀerences nor prepost diﬀerences in
each group were found (Figure 2). For the HR measure, we
only found a signiﬁcant prepost main eﬀect (F(1.9) = 32.497,
p < 0 001) that was conﬁrmed in both groups and corre-
sponded to a mild and not clinically relevant reduction of
heart rate (2.3 bpm in the real group and 4.7 bpm in the sham
group) (Figure 3).
After intervention, FMA scores were signiﬁcantly better
in the real group as compared to the sham group (Mann–
Whitney U = 5 00, p = 0 048) (Figure 4). Individual data,
including the kind of treatment (robotics and VNS), the
intensity of VNS, and the changes in FMA, HR, and blood
pressure are reported in Table 2.
4. Discussion
This is the ﬁrst study that has evaluated the feasibility of
tVNS in chronic both ischemic and haemorrhagic stroke
Table 1: Demographic and clinical characteristics of the patients at
baseline.
Real (N = 7) Sham (N = 5) p value
Age (years) 53.71± 5.88 55.60± 7.12 1.00a
Sex (M) 4 3 0.447b
Months since stroke 93.71± 38.81 46.00± 21.85 0.432a
Fugl–Meyer 22.29± 3.51 32.60± 6.43 0.268a
NIHSS 6.14± 1.50 4.80± 0.74 0.639a
Barthel Index 72.14± 9.81 81.00± 9.00 0.639a
Modiﬁed Rankin 2.86± 0.40 2.20± 0.58 0.432a
Modiﬁed Ashworth Scale
cumulative score
6.86± 1.16 5.40± 1.32 0.343a


















Figure 1: The eﬀect of tVNS on systolic BP.
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patients. Our data demonstrate that tVNS is safe and, com-
bined to robot-assisted rehabilitation, can induce a slight
but signiﬁcant improvement of arm functionality. The treat-
ment was well tolerated, and no adverse events or discom-
forts were reported from patients. In particular, we have
not recorded any side eﬀect that can occur with invasive
VNS such as vocal cord palsy, dysphagia, nausea, taste distur-
bance, hoarseness, or neck tingling [12]. Since vagus nerve
inﬂuences cardiac activity [18], we have carefully monitored
HR and BP during tVNS session in order to identify any
potential cardiovascular harm. We have not observed any
clinically signiﬁcant change in cardiovascular parameters
throughout the stimulation. A slight and asymptomatic
reduction of HRwas observed both in the real and in the sham
groups. Because this was present in both groups, it was not
related to tVNS and thus represents an unspeciﬁc change that
might be related to diﬀerent causes such as patient relaxation
during the course of the study. In a previous, randomized, pla-
cebo-controlled, double-blind study on ten healthy subjects
[14], we have showed that tVNS does not change HR and
BP. Similar results have been obtained from Shim et al. [19]
that have treated thirty patients with refractory chronic tinni-
tus. Taken together, these ﬁndings suggest that tVNS is a safe
technique that does not negatively inﬂuence cardiac function-
ality and can be used in stroke patients.
Even though this was a proof-of-principle study
mainly aimed to demonstrate the feasibility of tVNS, our
results suggest that the combination of vagal stimulation
and robotic rehabilitation can improve arm functionality
in chronic stroke patients. Indeed, both real and sham
patients improved after the intervention but the change
in FMA was signiﬁcantly higher for the real group (5.4
versus 2.8 points; p = 0 048). This change, although slight,
is considered clinically signiﬁcant in chronic patients [20],
especially in those with severe impairment of upper limb
function [2]. A potential beneﬁt of invasive VNS in
chronic stroke has been recently described both in animal
model [21] and in patients [12]. In a rat model of chronic
stroke, Khodaparast et al. [21] have demonstrated that VNS
paired with rehabilitative training signiﬁcantly improves
recovery of forelimb function compared to rehabilitation
alone. Interestingly, ischemic lesion size is not reduced by
VNS. According to the authors, this ﬁnding suggests that,
in chronic stroke, VNS promotes recovery through a mech-
anism independent of neuroprotection, most likely by
inducing neuroplasticity. This idea is further supported by
additional experimental data showing that VNS increases
levels of brain-derived neurotrophic factor (BDNF) and
neurotransmitters such as noradrenaline linked to neuro-
plasticity and recovery after brain lesion [22, 23].
The feasibility of VNS in chronic stroke patients has
been recently evaluated by a clinical trial involving twenty-

















































Figure 4: Eﬀect of tVNS on FMA scores. The FMA score improved
signiﬁcantly (∗p = 0 048) more in the real group than in the sham
group. FMA is expressed as percentage change with respect to
baseline.
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rehabilitation alone [12]. VNS has been performed by a sur-
gically implanted device producing stimulation paired with
rehabilitative exercises. The authors reported some minor
adverse eﬀects related to stimulating device, but no serious
adverse events were observed. Arm functionality, measured
by FMA, improved in both groups but more in the VNS
group (between-group diﬀerence, 5.7 points). In this trial,
VNS was delivered simultaneously with the rehabilitative
training. Indeed, animal studies [21] have demonstrated that
the timing of VNS-rehabilitation coupling is essential
because recovery does not improve when VNS follows reha-
bilitation. This result supports the idea that the synergistic
eﬀect of VNS and rehabilitation depends on neuroplasticity,
a timing-dependent phenomenon. Our study extends this
concept demonstrating that also noninvasive VNS delivered
before rehabilitation can ameliorate arm functionality. As
described for rTMS, tVNS could increase the eﬀect of reha-
bilitation by producing a priming eﬀect on subsequent
motor training [24].
Although intriguing, the results of our study, in particular
the eﬀect on FMA, should be considered cautiously. Indeed,
the present study has some important limitations such as
the small sample size, the use of diﬀerent kind of robotic
training, and the lack of a long-term follow-up.
5. Conclusions
Our pilot study conﬁrms that VNS is feasible and safe in
stroke patients and can produce a slight clinical improve-
ment in association to robotic rehabilitation. Compared to
traditional, invasive stimulation, tVNS seems to be safer
and more tolerable. Further studies are needed to conﬁrm
eﬃcacy and unveil the mechanisms of action of this innova-
tive approach.
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